SynthesisMolecular psychiatry2026
Integrating cell-type-specific gene expression and genome-wide associations identifies risk genes for schizophrenia.
Synthesis in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Integrative studies such as transcriptome-wide association studies (TWAS) and Mendelian randomization (MR) have identified multiple risk genes whose expression level is associated with schizophrenia (SCZ). However, the vast majority of integrative studies are based on quantitative trait loci (QTL) data from bulk brain tissues. Given that gene expression and genetic regulatory effects are highly dependent on cell types, it is important to conduct integrative studies using expression data from specific brain cell types. Here, we investigate the causality between cell-type-specific gene expression and SCZ. We first conducted MR by integrating four cell-type-specific expression quantitative trait loci (eQTL) datasets and genome-wide associations of SCZ separately. We then performed a meta-analysis to explore the causal relationships between gene expression in different human brain cell types and SCZ. We identified multiple genes whose cell-type-specific expression levels are causally associated with SCZ, including 148 significant genes in excitatory neurons, 71 in inhibitory neurons, 63 in astrocytes, 48 in microglia, 70 in oligodendrocytes, 39 in oligodendrocyte precursor cells, 20 in endothelial cells, and 7 in pericytes. We also performed MR using eQTL data from brain tissues and identified 206 genes whose expression levels are causally associated with SCZ. By integrating multiple lines of evidence, we prioritized the most plausible causal genes, including the MAU2 and PPP1R13B. Finally, we performed a drug target analysis to evaluate the therapeutic potential of these genes. Our study reveals the causal relationships between cell-type-specific gene expression and SCZ, providing promising targets for mechanistic investigation and therapeutic interventions.
Indexed as
Identifiers
42106519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.